Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) has been given a consensus recommendation of "Hold" by the six analysts that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.75.
Several equities analysts have issued reports on the company. Jefferies Financial Group lowered Forma Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $28.00 to $20.00 in a research note on Friday, September 2nd. HC Wainwright lowered Forma Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $53.00 to $20.00 in a research note on Friday, September 2nd. Oppenheimer lowered Forma Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 1st. Cantor Fitzgerald lowered Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 1st. Finally, Credit Suisse Group lowered Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 target price on the stock. in a research report on Friday, September 2nd.
Get
Forma Therapeutics alerts:
Hedge Funds Weigh In On Forma Therapeutics
A number of institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its holdings in Forma Therapeutics by 125.0% during the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after buying an additional 2,000 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Forma Therapeutics by 17,885.7% during the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after buying an additional 2,504 shares in the last quarter. Amalgamated Bank bought a new stake in Forma Therapeutics during the first quarter worth $38,000. US Bancorp DE grew its holdings in Forma Therapeutics by 282.5% during the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after buying an additional 3,206 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Forma Therapeutics by 56.3% during the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after buying an additional 3,670 shares in the last quarter. 87.39% of the stock is owned by institutional investors and hedge funds.
Forma Therapeutics Stock Performance
Shares of FMTX opened at $19.95 on Tuesday. Forma Therapeutics has a 52-week low of $4.95 and a 52-week high of $24.99. The business's 50 day moving average price is $14.79 and its two-hundred day moving average price is $10.07. The firm has a market cap of $954.61 million, a PE ratio of -4.99 and a beta of -0.31.
About Forma Therapeutics
(Get Rating)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
